WO2003025224A1 - Differential gene expression in schizophrenia - Google Patents

Differential gene expression in schizophrenia Download PDF

Info

Publication number
WO2003025224A1
WO2003025224A1 PCT/GB2002/004285 GB0204285W WO03025224A1 WO 2003025224 A1 WO2003025224 A1 WO 2003025224A1 GB 0204285 W GB0204285 W GB 0204285W WO 03025224 A1 WO03025224 A1 WO 03025224A1
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
gene expression
differential gene
methods
apolipoprotein
Prior art date
Application number
PCT/GB2002/004285
Other languages
French (fr)
Other versions
WO2003025224A3 (en
WO2003025224A8 (en
Inventor
Sabine Bahn
Original Assignee
Babraham Inst
Sabine Bahn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Inst, Sabine Bahn filed Critical Babraham Inst
Priority to AU2002324232A priority Critical patent/AU2002324232A1/en
Publication of WO2003025224A1 publication Critical patent/WO2003025224A1/en
Publication of WO2003025224A8 publication Critical patent/WO2003025224A8/en
Publication of WO2003025224A3 publication Critical patent/WO2003025224A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Evidence for up-regulation of apolipoprotein L1, L2 and L4 gene expression in the prefrontal cortex of schizophrenia brains is presented. Methods of diagnosis of schizophrenia and methods of identifying compounds with potential activity in the prevention, treatment, or amelioration of schizophrenia are described.
PCT/GB2002/004285 2001-09-21 2002-09-20 Differential gene expression in schizophrenia WO2003025224A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324232A AU2002324232A1 (en) 2001-09-21 2002-09-20 Differential gene expression in schizophrenia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0122789.1A GB0122789D0 (en) 2001-09-21 2001-09-21 Differential gene expression in schizophrenia

Publications (3)

Publication Number Publication Date
WO2003025224A1 true WO2003025224A1 (en) 2003-03-27
WO2003025224A8 WO2003025224A8 (en) 2003-06-05
WO2003025224A3 WO2003025224A3 (en) 2003-10-16

Family

ID=9922472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004285 WO2003025224A1 (en) 2001-09-21 2002-09-20 Differential gene expression in schizophrenia

Country Status (3)

Country Link
AU (1) AU2002324232A1 (en)
GB (1) GB0122789D0 (en)
WO (1) WO2003025224A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111270A2 (en) * 2003-06-13 2004-12-23 The Babraham Institute Differential gene expression in schizophrenia
US7670849B2 (en) 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels
WO2001057275A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels
WO2001057275A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"A transmission disequilibrium and linkage analysis of D22S278 marker alleles in 574 families: further support for a susceptibility locus for schizophrenia at 22q12. Schizophrenia Collaborative Linkage Group for Chromosome 22.", SCHIZOPHRENIA RESEARCH. NETHERLANDS 27 JUL 1998, vol. 32, no. 2, 27 July 1998 (1998-07-27), pages 115 - 121, XP002247905, ISSN: 0920-9964 *
BASSETT A S ET AL: "Genetic insights into schizophrenia", CANADIAN JOURNAL OF PSYCHIATRY 2001 CANADA, vol. 46, no. 2, 2001, pages 131 - 137, XP009013978, ISSN: 0706-7437 *
DUCHATEAU PHILIPPE N ET AL: "Apolipoprotein L gene family: Tissue-specific expression, splicing, promoter regions;discovery of a new gene.", JOURNAL OF LIPID RESEARCH, vol. 42, no. 4, April 2001 (2001-04-01), pages 620 - 630, XP002247906, ISSN: 0022-2275 *
MIMMACK MICHAEL L ET AL: "Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 2 APR 2002, vol. 99, no. 7, 2 April 2002 (2002-04-02), pages 4680 - 4685, XP002247907, ISSN: 0027-8424 *
PAGE N M ET AL: "The Human Apolipoprotein L Gene Cluster: Identification, Classification, and Sites of Distribution", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 74, no. 1, 15 May 2001 (2001-05-15), pages 71 - 78, XP004432227, ISSN: 0888-7543 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111270A3 (en) * 2003-06-13 2005-03-24 Babraham Inst Differential gene expression in schizophrenia
WO2004111270A2 (en) * 2003-06-13 2004-12-23 The Babraham Institute Differential gene expression in schizophrenia
US8968706B2 (en) 2005-04-29 2015-03-03 Robert I. Henkin Methods for diagnosing and treating loss or distortion of taste
US7670849B2 (en) 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US11389453B2 (en) 2005-04-29 2022-07-19 Cyrano Therapeutics, Inc. Compositions and methods for treating chemosensory dysfunction
US10206927B2 (en) 2005-04-29 2019-02-19 Cyrano Therapeutics, Inc. Compostions and methods for treating chemosensory dysfunction
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US9719988B2 (en) 2007-01-31 2017-08-01 Cyrano Therapeutics, Inc. Methods for detection of biological substances
US8663938B2 (en) 2007-01-31 2014-03-04 Robert I. Henkin Methods for detection of biological substances
US10555940B2 (en) 2008-07-23 2020-02-11 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11125760B2 (en) 2014-02-18 2021-09-21 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11774458B2 (en) 2014-02-18 2023-10-03 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell

Also Published As

Publication number Publication date
AU2002324232A1 (en) 2003-04-01
WO2003025224A3 (en) 2003-10-16
GB0122789D0 (en) 2001-11-14
WO2003025224A8 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
EP2453024A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2003020287A3 (en) Methods for the treatment of chronic pain anc compositions therefor
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
ATE357272T1 (en) USE OF PHTHALAZINE DERIVATIVES TO TREAT NEURODEGENERATIVE DISEASES
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
AU2002953327A0 (en) Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2006018632A3 (en) Cell therapy with exo 1
ATE444073T1 (en) OXALATE-DEGRADING MICROORGANISMS OR OXALATE-DEGRADING ENZYMES FOR PREVENTING OXALATE-RELATED DISEASES
WO2003025224A3 (en) Differential gene expression in schizophrenia
WO2000018912A3 (en) Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
EP1163515A4 (en) Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
WO2001042784A3 (en) Methods for screening compounds active on neurons
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
HK1042523A1 (en) Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
WO2004111270A3 (en) Differential gene expression in schizophrenia
WO1997042347A3 (en) 5-lipoxygenase gene polymorphisms and their use in classifying patients
PT1117409E (en) BENZENOSULFONIL (TIO) UREIAS IN ASSOCIATION WITH BETABLETS FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES AUTONOMOUS
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
AU1747295A (en) 4-amino 6-substituted mycophenolic acid and derivatives with immunosuppressive activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 12/2003 CLASSEE 13/2003 REPLACE ""A1"" BY ""A2"" AND UNDER ""PUBLISHED"", REPLACE ""WITH INTERNATIONAL SEARCH REPORT"" BY ""WITHOUT INTERNATIONAL SEARCH REPORT""

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP